Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)

• Company Description    Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $0.84 Daily Weekly Monthly 20 Day Moving Average: 515,579 shares Shares Outstanding: 31.15 (millions) Market Capitalization: $26.32 (millions) Beta: -0.31 52 Week High: $1.23 52 Week Low: $0.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 39.15% 34.32% 12 Week 3.68% 2.19% Year To Date 66.98% 46.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1951 NW 7TH AVENUE SUITE 520 - MIAMI,FL 33136 USA ph: 305-909-0840 fax: - investorrelations@firstcommunitysc.com https://longeveron.com

• General Corporate Information    Officers Stephen H. Willard - Chief Executive Officer Joshua M. Hare - Co-Founder; Chief Science Officer; Executive Chair Lisa A. Locklear - Chief Financial Officer and Treasurer George Paletta, Jr - Director Roger Hajjar - Director Peer Information Longeveron Inc. (CORR.) Longeveron Inc. (RSPI) Longeveron Inc. (CGXP) Longeveron Inc. (BGEN) Longeveron Inc. (GTBP) Longeveron Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 54303L203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/03/26 Share - Related Items Shares Outstanding: 31.15 Most Recent Split Date: 3.00 (0.10:1) Beta: -0.31 Market Capitalization: $26.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.68 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.53 Price/Cash Flow: - Price / Sales: 22.17 EPS Growth vs. Year Ago Period: 42.42% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -9.18% vs. Previous Quarter: -27.89% ROE 06/30/26 - -223.19 03/31/26 - -202.41 12/31/25 - -199.79 ROA 06/30/26 - -150.20 03/31/26 - -140.67 12/31/25 - -143.21 Current Ratio 06/30/26 - 2.63 03/31/26 - 3.88 12/31/25 - 1.33 Quick Ratio 06/30/26 - 2.63 03/31/26 - 3.88 12/31/25 - 1.33 Operating Margin 06/30/26 - -1,977.59 03/31/26 - -1,844.49 12/31/25 - -1,893.58 Net Margin 06/30/26 - -1,977.59 03/31/26 - -1,844.49 12/31/25 - -1,893.58 Pre-Tax Margin 06/30/26 - -1,977.59 03/31/26 - -1,844.49 12/31/25 - -1,893.58 Book Value 06/30/26 - 0.33 03/31/26 - 0.69 12/31/25 - 0.25 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.05 12/31/25 - 0.03 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 4.63 12/31/25 - 2.89

Powered by Zacks Investment Research ©